BioNexus Gene Lab Inventory 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab inventory from 2019 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$93.6B
Cencora (COR)	$48.4B
DiDi Global (DIDIY)	$22.9B
Natera (NTRA)	$22.4B
ICON (ICLR)	$17.6B
Viatris (VTRS)	$15.8B
Avantor (AVTR)	$13.9B
Revvity (RVTY)	$13.5B
CochLear (CHEOY)	$12.6B
BioMerieux (BMXMF)	$12.1B
Solventum (SOLV)	$12B
Medpace Holdings (MEDP)	$10.6B
Charles River Laboratories (CRL)	$9.9B
HealthEquity (HQY)	$9.1B
Doximity (DOCS)	$9B
Sonic Healthcare (SKHHY)	$8.8B
Bausch + Lomb (BLCO)	$7B
Life Times (LTH)	$5B
Organon (OGN)	$3.8B
Sotera Health (SHC)	$3.5B
BrightSpring Health Services (BTSG)	$3.3B
Surgery Partners (SGRY)	$3B
Concentras Parent (CON)	$2.7B
PACS (PACS)	$2.5B
Alignment Healthcare (ALHC)	$2.3B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.2B
Ryman Healthcare (RYHTY)	$2B
GeneDx Holdings (WGS)	$2B
Teladoc Health (TDOC)	$1.8B